• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Maurizio Fava, MD


  • Janes AC, Pizzagalli DA, Richardt S, Frederick Bde B, Holmes AJ, Sousa J, Fava M, Evins AE, Kaufman MJ.Neural substrates of attentional bias for smoking-related cues: an FMRI study.Neuropsychopharmacology. 2010 Nov;35(12):2339-45.
  • Kim BW, Kennedy DN, Leh├ír J, Lee MJ, Blood AJ, Lee S, Perlis RH, Smoller JW, Morris R, Fava M, Breiter HC, .Recurrent, robust and scalable patterns underlie human approach and avoidance.PLoS ONE. 2010;5(5):e10613.
  • Janes AC, Pizzagalli DA, Richardt S, Frederick BD, Chuzi S, Pachas G, Culhane MA, Holmes AJ, Fava M, Evins AE, Kaufman MJ.Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence.Biol Psychiatry. 2010 Apr 15;67(8):722-9.
  • Janes AC, Frederick B, Richardt S, Burbridge C, Merlo-Pich E, Renshaw PF, Evins AE, Fava M, Kaufman MJ.Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence.Exp Clin Psychopharmacol. 2009 Dec;17(6):365-73.
  • Mischoulon D, Burger JK, Spillmann MK, Worthington JJ, Fava M, Alpert JE.Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression.J Psychosom Res. 2000 Sep;49(3):183-7.
  • Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL.A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.Ann Clin Psychiatry. 1998 Dec;10(4):145-50.
  • Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB.Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.Biol Psychiatry. 1998 Jul 15;44(2):77-87.
  • Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P.Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.Arch Gen Psychiatry. 1998 Apr;55(4):334-43.
  • Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF.Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.Am J Psychiatry. 1997 Dec;154(12):1760-2.
  • Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, Rosenbaum J, Harrison W.A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia.Arch Gen Psychiatry. 1996 Sep;53(9):777-84.
  • Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF.Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.J Clin Psychiatry. 1995 Feb;56(2):52-5.
  • Rosenbaum JF, Fava M, Pava JA, McCarthy MK, Steingard RJ, Bouffides E.Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and changes following fluoxetine treatment.Am J Psychiatry. 1993 Aug;150(8):1164-8.
  • Fava M, Rosenbaum JF, Cohen L, Reiter S, McCarthy M, Steingard R, Clancy K.High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine.J Affect Disord. 1992 Aug;25(4):229-34.
  • Fava M, Rosenbaum JF.Suicidality and fluoxetine: is there a relationship?.J Clin Psychiatry. 1991 Mar;52(3):108-11.
  • Rosenbaum JF, Fava M, Falk WE, Pollack MH, Cohen LS, Cohen BM, Zubenko GS.The antidepressant potential of oral S-adenosyl-l-methionine.Acta Psychiatr Scand. 1990 May;81(5):432-6.